Context Therapeutics (NASDAQ:CNTX) Inc has told investors that an abstract on the results of the monotherapy portion of its ongoing Phase 2 trial of lead candidate onapristone extended release (ONA-XR) in granulosa cell tumors of the ovary was accepted for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
The meeting takes place from June 3-7, 2022, at the McCormick Place Convention Center in Chicago, Illinois.
"We are thrilled that ASCO has recognized the potential of our novel clinical program for ONA-XR, a potent, specific progesterone receptor (PR) antagonist, in the treatment of granulosa cell tumors (GCTs) of the ovary," the company’s CEO Martin Lehr said in a statement.
READ: Context Therapeutics reveals “encouraging” preclinical data from two cancer-treating pipeline programs
"GCTs are a rare form of ovarian cancer that is highly enriched for the target of ONA-XR. We look forward to sharing the stage I monotherapy data at the conference and continuing enrollment of the stage II portion evaluating the combination of ONA-XR plus the antiestrogen anastrozole,” Lehr added.
Presentation details:
- Title: Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous carcinoma ovarian (LGSOC), or endometrioid endometrial cancer (EEC)
- Session type/title: Poster Discussion Session, Gynecologic Cancer
- Session date and time: Saturday, June 4, 2022 from 1.15pm to 4.15pm central time
- Abstract Number: 5521
- Presenter: Rachel Grisham, MD, Memorial Sloan-Kettering Cancer Center
Based in Philadelphia, Context Therapeutics (NASDAQ:CNTX) is a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers.
Its clinical program for lead candidate onapristone extended release (ONA-XR) consists of three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian, and endometrial cancer.
ONA-XR is a novel, first-in-class small molecule under development as a potent and specific antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women's cancers.
Contact the author at stephen.gunnion@proactiveinvestors.com